Targeted co-delivery of polypyrrole and rapamycin by trastuzumab-conjugated liposomes for combined chemo-photothermal therapy

International Journal of Pharmaceutics
Hanh Thuy NguyenJong Oh Kim

Abstract

Trastuzumab is a therapeutic monoclonal antibody that selectively recognizes HER2/neu receptor for targeting breast cancers. In this study, we aimed to present a strategy to combine chemo and phototherapy and targeted delivery via monoclonal antibody for enhanced anticancer effects. We co-loaded a chemotherapeutic agent, rapamycin, and a photosensitizer, polypyrrole, in trastuzumab-conjugated liposomes (LRPmAb) for combined chemo-photothermal therapy. LRPmAb had small size (172.2±9.6nm), narrow distribution, and negative ζ-potential (-12.0±0.3mV). In addition, LRPmAb showed pH- and temperature-dependent release profiles. LRPmAb showed significantly enhanced uptake in BT-474 cells, a natural HER2/neu expressing cell line. We found that these LRPmAb were effective in delivering rapamycin and showed higher therapeutic efficacy in breast cancer cells overexpressing HER2/neu receptors compared with cells that did not overexpress these receptors. Furthermore, LRPmAb showed synergistic activity against rapamycin-sensitive and resistant cell lines in vitro. These findings indicated that LRPmAb-mediated drug delivery could improve the therapeutic efficacy against breast cancer and overcome drug resistance.

Citations

Aug 1, 2019·Current Pharmaceutical Biotechnology·Hasanain Gomhor J AlqaraghuliRonak Rafipour
Apr 10, 2019·Polymers·Jeremy B VinesHansoo Park
Sep 29, 2019·Biomolecules·Shima TavakolAlan Prem Kumar
Jan 30, 2020·Archives of Pharmacal Research·Cao Dai PhungJong Oh Kim
Aug 30, 2020·Nanomaterials·Celia NietoEva M Martín Del Valle
Sep 6, 2019·Pharmaceutical Nanotechnology·Ranjit K HarwanshMd Akhlaquer Rahman
Jul 3, 2019·Nanomaterials·Celia NietoEva M Martín Del Valle
Apr 10, 2019·Polymers·Monika Tomczykowa, Marta Eliza Plonska-Brzezinska
Aug 2, 2019·Cancer Chemotherapy and Pharmacology·A I Fraguas-SánchezA I Torres-Suárez
Mar 4, 2021·Pharmaceutical Research·Radhika Narayanaswamy, Vladimir P Torchilin
Jan 23, 2020·Current Medicinal Chemistry·Amanda Letícia Polli SilvestreMarlus Chorilli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.